Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 64Head and Neck Neoplasms 63Squamous Cell Carcinoma of Head and Neck 60Carcinoma, Non-Small-Cell Lung 34Rectal Neoplasms 23Colonic Neoplasms 23Neoplasm Metastasis 19Neoplasms 18Carcinoma, Squamous Cell 17Pancreatic Neoplasms 13Lung Neoplasms 13Esophageal Neoplasms 11Tongue Neoplasms 9Stomach Neoplasms 9Recurrence 9Carcinoma 8Neoplasms, Squamous Cell 6Mouth Neoplasms 6Laryngeal Neoplasms 6Breast Neoplasms 6Adenocarcinoma Of Esophagus 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Esophageal Squamous Cell Carcinoma 5Adenocarcinoma of Lung 5Sarcoma 4Salivary Gland Neoplasms 4Oropharyngeal Neoplasms 4Laryngeal Diseases 4Precancerous Conditions 3Hypopharyngeal Neoplasms 3

Interventions

pembrolizumab 37Paclitaxel 36Carboplatin 31Cyclophosphamide 22Albumin-Bound Paclitaxel 20atezolizumab 16130-nm albumin-bound paclitaxel 16Taxes 15Doxorubicin 15Cisplatin 13Capecitabine 13Nivolumab 10Docetaxel 8olaparib 7Gemcitabine 6Everolimus 6talazoparib 5durvalumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Bevacizumab 5veliparib 4spartalizumab 4sacituzumab govitecan 4pegfilgrastim 4liposomal doxorubicin 4eribulin 4Specimen Handling 4Immunoglobulin G 4trilaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Triple Negative Breast Neoplasms × Cetuximab × Clear all
NCT01451632 2016-09-08

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Merrimack Pharmaceuticals

Phase 1 Completed
48 enrolled 14 charts
BreastGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡